G1 THERAPEUTICS INC. - COMMON STOCK

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

28 фев 2024 05:30:52 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

27 фев 2024 07:30:01 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

15 фев 2024 07:30:28 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

12 фев 2024 15:05:18 Источник Nasdaq GlobeNewswire

G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference

08 янв 2024 05:45:52 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 08:00:17 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 янв 2024 15:51:10 Источник Nasdaq GlobeNewswire

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy

05 дек 2023 08:26:20 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 дек 2023 15:27:24 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium

29 ноя 2023 19:37:45 Источник Nasdaq GlobeNewswire

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

01 ноя 2023 05:30:53 Источник Nasdaq GlobeNewswire

Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

27 окт 2023 06:00:54 Источник Nasdaq GlobeNewswire

G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)

18 окт 2023 07:00:50 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023

18 окт 2023 06:30:06 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium

16 окт 2023 08:00:33 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

05 сен 2023 10:00:29 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 сен 2023 15:15:21 Источник Nasdaq GlobeNewswire

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights

02 авг 2023 05:30:27 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Participate in Two August Investor Conferences

31 июл 2023 13:30:27 Источник Nasdaq GlobeNewswire

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

31 июл 2023 07:30:40 Источник Nasdaq GlobeNewswire